Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease (Q61924896)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease |
clinical trial |
Statements
ACCELA (English)
0 references
A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial of HMR1766 Assessing the Efficacy and Safety of 3 Doses of HMR1766 Versus Placebo With Cilostazol as a Calibrator, Administered for 26 Weeks in Patients With Peripheral Arterial Disease (PAD) Fontaine Stage II (English)
0 references
February 2007
0 references
October 2008
0 references
553
0 references
40 year
0 references